Trellis Bioscience, Inc.
StreetZero Signal 75
About Trellis Bioscience, Inc.
Trellis Bioscience, Inc. is a clinical-stage biotechnology company developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases. Its lead candidate, calpurbatug (TRL1068), is an investigational mAb for chronic prosthetic joint infections (PJI). The company leverages a platform technology for discovering therapeutic antibodies at the single-cell level. It is headquartered in Redwood City, California, and was founded in 1998.
LATEST FUNDINGPrivate Placement
$4.1M
Announced 2026-10-21
TOTAL RAISED$50.64M
IN THE NEWS
- 🔗 TRELLIS BIOSCIENCE RAISES $9 MILLION TO ADVANCE CLINICAL DEVELOPMENT OF CALPURBATUG (TRL1068)
- 🔗 Trellis Bioscience - 2026 Company Profile, Funding & Competitors - Tracxn
- 🔗 Trellis raises Series C to fund TRL1068 trial | Clinical Trials Arena
- 🔗 Trellis Bioscience Inc. — Funding, Investors & Signals 2026 - Bounce Watch
- 🔗 Trellis Bioscience - Products, Competitors, Financials, Employees, Headquarters Locations
EMPLOYEES—
FOUNDED1998
HQRedwood City, CA, United States
Industry
Biotechnology
Tags
BiotechnologyMonoclonal AntibodiesClinical-StageInfectious Diseases
Key highlights
- Closed $9M Series C in July 2026 to complete Phase 2 trial of TRL1068 for prosthetic joint infections.
- Platform technology previously backed by top-tier VCs; product development funded by AMR Action Fund and KOLs.
- Total equity funding near $35M with matching non-dilutive grants from NIAID and CARB-X.
- Principal from AMR Action Fund joined the board following the investment.
Ask StreetZero about Trellis Bioscience, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account